Literature DB >> 32081643

Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis.

Gabriela R Oates1, Elizabeth Baker2, Steven M Rowe2, Hector H Gutierrez2, Michael S Schechter3, Wayne Morgan4, William T Harris5.   

Abstract

BACKGROUND: Pulmonary decline in CF is heterogeneous, with socio-environmental factors contributing to this variability. Few studies have attempted to disentangle the effects of tobacco smoke exposure and socioeconomic factors on lung function deterioration in pediatric CF. The current study evaluates their contributions longitudinally across the entire U.S. CF care network population.
METHODS: Data from the CF Foundation Patient Registry were obtained on all individuals who at the end of 2016 were 6-18 years old. Lung function measures (ppFEV1) for each person were calculated at each attained age. Multivariable analyses used mixed modeling to assess the impact of smoke exposure and socioeconomic factors on initial lung function and change over time.
RESULTS: The sample included 10,895 individuals contributing 65,581 person years. At age 6, ppFEV1 of smoke-exposed children was 4.7% lower than among unexposed. The deficit persisted through age 18. In adjusted mixed models, smoke exposure and socioeconomic factors had independent, additive associations with lung function. Median ppFEV1 declined 2.4% with smoke exposure, 4.9% with lower paternal education, 0.3% with public insurance, and increased 0.2% with each $10,000 annual household income. The effect of smoke exposure on ppFEV1 was larger in disadvantaged children compared to privileged counterparts (3.2% vs 1.2%).
CONCLUSIONS: Smoke exposure and socioeconomic factors are independent risk factors for decreased ppFEV1 in pediatric CF. Smoking cessation strategies should be emphasized at the time of CF diagnosis and reiterated during infancy and early childhood. Interventions may be prioritized in disadvantaged families, where the exposure has a disproportionately large effect.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32081643      PMCID: PMC7429279          DOI: 10.1016/j.jcf.2020.02.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  25 in total

1.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

Review 2.  Nongenetic influences on cystic fibrosis outcomes.

Authors:  Michael S Schechter
Journal:  Curr Opin Pulm Med       Date:  2011-11       Impact factor: 3.155

3.  Early Postnatal Secondhand Smoke Exposure Disrupts Bacterial Clearance and Abolishes Immune Responses in Muco-Obstructive Lung Disease.

Authors:  Brandon W Lewis; Razia Sultana; Rahul Sharma; Alexandra Noël; Ingeborg Langohr; Sonika Patial; Arthur L Penn; Yogesh Saini
Journal:  J Immunol       Date:  2017-06-30       Impact factor: 5.422

4.  Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.

Authors:  Lacrecia J Britton; Gabriela R Oates; Robert A Oster; Staci T Self; Robert B Troxler; Wynton C Hoover; Hector H Gutierrez; William T Harris
Journal:  Pediatr Pulmonol       Date:  2016-08-24

5.  Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.

Authors:  J Michael Collaco; Lori Vanscoy; Lindsay Bremer; Kathryn McDougal; Scott M Blackman; Amanda Bowers; Kathleen Naughton; Jacky Jennings; Jonathan Ellen; Garry R Cutting
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 6.  Impact of Tobacco Smoke and Nicotine Exposure on Lung Development.

Authors:  Kevin Gibbs; Joseph M Collaco; Sharon A McGrath-Morrow
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

7.  Comparison of Urine 4-(Methylnitrosamino)-1-(3)Pyridyl-1-Butanol and Cotinine for Assessment of Active and Passive Smoke Exposure in Urban Adolescents.

Authors:  Neal L Benowitz; Natalie Nardone; Shonul Jain; Delia A Dempsey; Newton Addo; Gideon St Helen; Peyton Jacob
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-02-23       Impact factor: 4.254

8.  Stages of the cigarette epidemic on entering its second century.

Authors:  Michael Thun; Richard Peto; Jillian Boreham; Alan D Lopez
Journal:  Tob Control       Date:  2012-03       Impact factor: 7.552

9.  Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study.

Authors:  Helen L Barr; John Britton; Alan R Smyth; Andrew W Fogarty
Journal:  BMJ       Date:  2011-08-23

10.  The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study.

Authors:  David C Taylor-Robinson; Rosalind L Smyth; Peter J Diggle; Margaret Whitehead
Journal:  Lancet Respir Med       Date:  2013-01-30       Impact factor: 30.700

View more
  13 in total

Review 1.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

2.  Tobacco smoke exposure in pediatric cystic fibrosis: A qualitative study of clinician and caregiver perspectives on smoking cessation.

Authors:  Gabriela R Oates; William T Harris; Hector H Gutierrez; Cathy Mims; Sarah B Rutland; Corilyn Ott; Soumya J Niranjan; Isabel C Scarinci; Susan C Walley
Journal:  Pediatr Pulmonol       Date:  2020-06-08

3.  The association of area deprivation and state child health with respiratory outcomes of pediatric patients with cystic fibrosis in the United States.

Authors:  Gabriela Oates; Sarah Rutland; Lucia Juarez; Annabelle Friedman; Michael S Schechter
Journal:  Pediatr Pulmonol       Date:  2020-12-14

Review 4.  Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Authors:  Meghan E McGarry; Elizabeth R Gibb; Gabriela R Oates; Michael S Schechter
Journal:  Paediatr Respir Rev       Date:  2021-12-22       Impact factor: 5.526

5.  Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Ann Am Thorac Soc       Date:  2021-02

Review 6.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

7.  Metabolomics profiling of tobacco exposure in children with cystic fibrosis.

Authors:  Benjamin L Wisniewski; Chandra L Shrestha; Shuzhong Zhang; Rohan Thompson; Myron Gross; Judith A Groner; Karan Uppal; Octavio Ramilo; Asuncion Mejias; Benjamin T Kopp
Journal:  J Cyst Fibros       Date:  2020-05-30       Impact factor: 5.482

8.  Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data.

Authors:  Gabriela R Oates; Elizabeth Baker; Joseph M Collaco; Steven M Rowe; Sarah B Rutland; Christopher M Fowler; William T Harris
Journal:  J Cyst Fibros       Date:  2021-07-17       Impact factor: 5.527

9.  Association between insurance variability and early lung function in children with cystic fibrosis.

Authors:  Kimberly M Dickinson; Kevin J Psoter; Kristin A Riekert; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2021-06-24       Impact factor: 5.482

10.  Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.

Authors:  Elizabeth Baker; William T Harris; Steven M Rowe; Sarah B Rutland; Gabriela R Oates
Journal:  J Cyst Fibros       Date:  2020-10-03       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.